TYK2-STAT1-BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia.

Cancer Discov
Publication Year: 
Takaomi Sanda
Jeffrey W Tyner
Alejandro Gutierrez
Vu N Ngo
Jason Glover
Bill H Chang
Arla Yost
Wenxue Ma
Angela G Fleischman
Wenjun Zhou
Yandan Yang
Maria Kleppe
Yebin Ahn
Jessica Tatarek
Michelle A Kelliher
Donna S Neuberg
Ross L Levine
Richard Moriggl
Mathias Muller
Nathanael S Gray
Catriona H M Jamieson
Andrew P Weng
Louis M Staudt
Brian J Druker
A Thomas Look
PubMed link: 
Public Summary: 
In recent years, “pathway dependence” has been revealed in specifi c types of human cancer, which can be important because they pinpoint proteins that are particularly vulnerable to antitumor-targeted inhibition (so-called Achilles’ heel proteins). Here, we use RNAi technology to identify a novel oncogenic pathway that involves aberrant activation of the TYK2 tyrosine kinase and its downstream substrate, STAT1, which ultimately promotes T-ALL cell survival through the upregulation of BCL2 expression. Cancer Discov; 3(5); 564–77. ©2013 AACR.
Scientific Abstract: 
Targeted molecular therapy has yielded remarkable outcomes in certain cancers, but specific therapeutic targets remain elusive for many others. As a result of two independent RNA interference (RNAi) screens, we identified pathway dependence on a member of the Janus-activated kinase (JAK) tyrosine kinase family, TYK2, and its downstream effector STAT1, in T-cell acute lymphoblastic leukemia (T-ALL). Gene knockdown experiments consistently showed TYK2 dependence in both T-ALL primary specimens and cell lines, and a small-molecule inhibitor of JAK activity induced T-ALL cell death. Activation of this TYK2-STAT1 pathway in T-ALL cell lines occurs by gain-of-function TYK2 mutations or activation of interleukin (IL)-10 receptor signaling, and this pathway mediates T-ALL cell survival through upregulation of the antiapoptotic protein BCL2. These findings indicate that in many T-ALL cases, the leukemic cells are dependent upon the TYK2-STAT1-BCL2 pathway for continued survival, supporting the development of molecular therapies targeting TYK2 and other components of this pathway.